Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out

The role of adjuvant radiotherapy in completely resected pIIIA‐N2 non‐small cell lung cancer (NSCLC) has long been debated. Evidence from previous retrospective and prospective studies showed that postoperative radiotherapy could reduce the incidence of local recurrence and prolong disease‐free surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Lucheng, Xia, Bing, Ma, Shenglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888147/
https://www.ncbi.nlm.nih.gov/pubmed/35106937
http://dx.doi.org/10.1111/1759-7714.14335
_version_ 1784661071813935104
author Zhu, Lucheng
Xia, Bing
Ma, Shenglin
author_facet Zhu, Lucheng
Xia, Bing
Ma, Shenglin
author_sort Zhu, Lucheng
collection PubMed
description The role of adjuvant radiotherapy in completely resected pIIIA‐N2 non‐small cell lung cancer (NSCLC) has long been debated. Evidence from previous retrospective and prospective studies showed that postoperative radiotherapy could reduce the incidence of local recurrence and prolong disease‐free survival, while two recently reported randomized controlled trials (lung ART and PORT‐C) both demonstrated no survival benefit of postoperative radiotherapy. The great gap between our knowledge and reality has made us rethink the value of postoperative radiotherapy. In this mini review, we elaborate on the role of postoperative radiotherapy in completely resected pIIIA‐N2 NSCLC.
format Online
Article
Text
id pubmed-8888147
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-88881472022-03-04 Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out Zhu, Lucheng Xia, Bing Ma, Shenglin Thorac Cancer Mini Review The role of adjuvant radiotherapy in completely resected pIIIA‐N2 non‐small cell lung cancer (NSCLC) has long been debated. Evidence from previous retrospective and prospective studies showed that postoperative radiotherapy could reduce the incidence of local recurrence and prolong disease‐free survival, while two recently reported randomized controlled trials (lung ART and PORT‐C) both demonstrated no survival benefit of postoperative radiotherapy. The great gap between our knowledge and reality has made us rethink the value of postoperative radiotherapy. In this mini review, we elaborate on the role of postoperative radiotherapy in completely resected pIIIA‐N2 NSCLC. John Wiley & Sons Australia, Ltd 2022-02-02 2022-03 /pmc/articles/PMC8888147/ /pubmed/35106937 http://dx.doi.org/10.1111/1759-7714.14335 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mini Review
Zhu, Lucheng
Xia, Bing
Ma, Shenglin
Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
title Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
title_full Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
title_fullStr Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
title_full_unstemmed Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
title_short Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
title_sort postoperative radiotherapy for patients with completely resected stage iiia‐n2 non‐small cell lung cancer: opt‐in or opt‐out
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888147/
https://www.ncbi.nlm.nih.gov/pubmed/35106937
http://dx.doi.org/10.1111/1759-7714.14335
work_keys_str_mv AT zhulucheng postoperativeradiotherapyforpatientswithcompletelyresectedstageiiian2nonsmallcelllungcanceroptinoroptout
AT xiabing postoperativeradiotherapyforpatientswithcompletelyresectedstageiiian2nonsmallcelllungcanceroptinoroptout
AT mashenglin postoperativeradiotherapyforpatientswithcompletelyresectedstageiiian2nonsmallcelllungcanceroptinoroptout

Ejemplares similares